131 536

Cited 0 times in

MicroRNA-155 regulates the Th17 immune response by targeting Ets-1 in Behcet's disease

DC Field Value Language
dc.contributor.authorNa, SY-
dc.contributor.authorPark, MJ-
dc.contributor.authorPark, S-
dc.contributor.authorLee, ES-
dc.date.accessioned2018-05-04T00:25:41Z-
dc.date.available2018-05-04T00:25:41Z-
dc.date.issued2016-
dc.identifier.issn0392-856X-
dc.identifier.urihttp://repository.ajou.ac.kr/handle/201003/15034-
dc.description.abstractOBJECTIVES: The goal of this study was to investigate whether microRNA-155 might be a potential therapeutic target for Behcet's disease (BD). METHODS: Expression levels of miR-155 were quantified using TaqMan microRNA assays in peripheral blood mononuclear cells and in isolated CD4+ T cells from BD patients and healthy controls. To identify targets of miR-155, luciferase reporter assays and western blotting were performed. The effect of miR-155 on Th17 polarisation was analysed in patients with active BD by using flow cytometry and enzyme-linked immunosorbent assay. RESULTS: The expression of miR-155 and IL-17 was significantly increased in CD4+ T cells of patients with active BD. A luciferase reporter assay and western blot showed that Ets-1 expression was reduced by miR-155 mimics. Furthermore, the expression of Ets-1 was significantly decreased in patients with active BD compared to healthy controls. More importantly, repression of miR-155 in CD4+ T cells from active BD patients increased Ets-1 expression and reduced the number of IL- 17-expressing T cells and overall IL-17 production. CONCLUSIONS: MiR-155 regulates the Th17 immune response by targeting Ets-1. Suppression of miR-155 reduced the amount of pathogenic IL-17-expressing T cells and may be a potential therapeutic strategy for BD.-
dc.formatapplication/pdf-
dc.language.isoen-
dc.subject.MESHAdult-
dc.subject.MESHBehcet Syndrome/genetics-
dc.subject.MESHBehcet Syndrome/immunology-
dc.subject.MESHBehcet Syndrome/metabolism-
dc.subject.MESHCase-Control Studies-
dc.subject.MESHCells, Cultured-
dc.subject.MESHFemale-
dc.subject.MESHGene Expression Regulation-
dc.subject.MESHGenes, Reporter-
dc.subject.MESHHumans-
dc.subject.MESHInterleukin-17/immunology-
dc.subject.MESHInterleukin-17/metabolism-
dc.subject.MESHMale-
dc.subject.MESHMicroRNAs/genetics-
dc.subject.MESHMicroRNAs/metabolism-
dc.subject.MESHMiddle Aged-
dc.subject.MESHPhenotype-
dc.subject.MESHProto-Oncogene Protein c-ets-1/genetics-
dc.subject.MESHProto-Oncogene Protein c-ets-1/metabolism-
dc.subject.MESHSignal Transduction-
dc.subject.MESHTh17 Cells/immunology-
dc.subject.MESHTh17 Cells/metabolism-
dc.subject.MESHTime Factors-
dc.subject.MESHTransfection-
dc.titleMicroRNA-155 regulates the Th17 immune response by targeting Ets-1 in Behcet's disease-
dc.typeArticle-
dc.identifier.pmid27156371-
dc.identifier.urlhttp://www.clinexprheumatol.org/pubmed/find-pii.asp?pii=27156371-
dc.contributor.affiliatedAuthor박, 선-
dc.contributor.affiliatedAuthor이, 은소-
dc.type.localJournal Papers-
dc.citation.titleClinical and experimental rheumatology-
dc.citation.volume34-
dc.citation.number6 Suppl 102-
dc.citation.date2016-
dc.citation.startPageS56-
dc.citation.endPageS63-
dc.identifier.bibliographicCitationClinical and experimental rheumatology, 34(6 Suppl 102). : S56-S63, 2016-
dc.embargo.liftdate9999-12-31-
dc.embargo.terms9999-12-31-
dc.identifier.eissn1593-098X-
dc.relation.journalidJ00392856X-
Appears in Collections:
Journal Papers > School of Medicine / Graduate School of Medicine > Microbiology
Journal Papers > School of Medicine / Graduate School of Medicine > Dermatology
Files in This Item:
27156371.pdfDownload

qrcode

해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse